Urcosimod for Eye Pain

(NEPTUNE Trial)

This trial tests Urcosimod eye drops to determine their effectiveness in relieving Neuropathic Corneal Pain (NCP), a type of eye pain that may feel like burning, stinging, or light sensitivity. The trial compares the effects of Urcosimod drops to a placebo (a solution with no active medication) to identify which works better. Individuals who have experienced eye pain for at least three months and have symptoms like burning or discomfort might be suitable candidates. Participants must apply the drops four times a day in the affected eye(s). As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of a new treatment.

Research shows that urcosimod, the eye drop being tested for nerve-related eye pain, has potential to reduce this pain. In earlier studies, patients generally tolerated urcosimod well. These studies did not report any major side effects, suggesting it might be safe to use. The FDA has approved its use for patients with severe pain outside of clinical trials, indicating a positive safety profile. However, while these results are promising, ongoing studies continue to evaluate its safety and effectiveness.¹²³⁴⁵

Urcosimod is unique because it offers a new approach to treating eye pain by using a novel active ingredient, urcosimod, in an ophthalmic solution. Unlike traditional treatments that primarily focus on anti-inflammatory or lubricating effects, urcosimod targets specific pathways that may more directly alleviate pain in the eye. Researchers are particularly excited about this treatment due to its potential to provide faster and more targeted relief compared to existing therapies. Additionally, its administration as an eye drop, four times a day, makes it user-friendly and easy to incorporate into daily routines.

Research has shown that Urcosimod eye drops yield promising results for treating nerve-related corneal pain. In earlier studies, 75% of patients using Urcosimod reported more than an 80% reduction in pain after 12 weeks, measured with a simple pain rating scale. Additionally, Urcosimod reduced inflammation and pain in animal studies. In this trial, participants will receive either Urcosimod ophthalmic solution or a vehicle ophthalmic solution as a placebo comparator. These findings suggest that Urcosimod could effectively treat this type of eye pain.⁶⁷⁸⁹¹⁰